• CytomX Therapeutics’ annual report for the year ended Dec. 31, 2025 highlighted positive Phase 1 data for its lead EpCAM Probody ADC Varseta-M in late-line metastatic colorectal cancer, supporting plans to advance the program toward a registrational study.
• Regulatory discussions are targeted in 2026, with an initial registrational study start aimed for the first half of 2027.
• Development is also shifting into combinations, with a Phase 1 Varseta-M study with bevacizumab already underway, an additional Phase 1b/2 study with bevacizumab and chemotherapy expected to start by end-2026.
• The report also flagged continued Phase 1 progress for CX-801 in advanced melanoma, with initial combination data with Merck’s Keytruda expected by end-2026.
• Management said it strengthened its financial position to support continued pipeline execution.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CytomX Therapeutics Inc. published the original content used to generate this news brief on May 21, 2026, and is solely responsible for the information contained therein.